Related Experiment Video
Updated: Feb 27, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection
Marion G Peters1, Stephen Locarnini1
1Dr Peters is a professor of medicine and chief of hepatology research in the Department of Medicine at the University of California in San Francisco, California. Dr Locarnini is a professor of microbiology and immunology at the University of Melbourne and is director of the WHO Regional Reference Laboratory for Hepatitis B within the Victorian Infectious Diseases Reference Laboratory at the Doherty Institute in Melbourne, Australia.
Abstract:
Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response. When discussing new therapies for CHB, it is critical to understand both the various phases of CHB and the life cycle of HBV. This article will discuss both of these issues, as well as mechanisms of action of potential therapies and possible ways to combine such therapies in the various phases of CHB.
Insights
New treatments for chronic hepatitis B (CHB) are in development, targeting the hepatitis B virus (HBV) life cycle and immune response. Understanding CHB phases and HBV life cycle is key for effective new therapy combinations.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B (CHB) impacts over 350 million globally, being a leading cause of liver cancer.
- Current CHB therapies manage the condition but do not offer a cure.
- CHB affects 2-3 million in the U.S. alone.
Purpose of the Study:
- To review the various phases of CHB and the hepatitis B virus (HBV) life cycle.
- To discuss the mechanisms of action for novel CHB therapeutic molecules.
- To explore potential combination strategies for new CHB therapies across different disease phases.
Main Methods:
- Review of preclinical and phase 2 studies for over 30 new molecules targeting HBV.
- Analysis of HBV life cycle and host immune response pathways.
- Examination of therapeutic strategies for CHB management.
Main Results:
- Over 30 novel molecules are under investigation, targeting distinct aspects of HBV replication and host immunity.
- Understanding of HBV lifecycle and CHB disease progression is crucial for therapeutic development.
- Potential for combination therapies exists to improve CHB treatment outcomes.
Conclusions:
- Novel therapeutic approaches for CHB are emerging, focusing on specific viral and host targets.
- A comprehensive understanding of CHB phases and HBV biology is essential for advancing treatment.
- Future CHB treatment may involve combination therapies tailored to disease stage.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency...